Design and synthesis of non-TZD peroxisome proliferator-activated receptor Î³ (PPARÎ³) modulator

Deka, N.; Uravane, M.; Anthony, J.; Bhumra, S.; Nair, A.; B-Rao, C.; Patel, Dharmeshkumar; Sivaramakrishnan, H.

doi:10.1007/s00044-013-0814-y

Access Status

Fulltext not available

Authors

Deka, N.

Uravane, M.

Anthony, J.

Bhumra, S.

Nair, A.

B-Rao, C.

Patel, Dharmeshkumar

Sivaramakrishnan, H.

Date

2014

Type

Journal Article

Metadata

Show full item record

Citation

Deka, N. and Uravane, M. and Anthony, J. and Bhumra, S. and Nair, A. and B-Rao, C. and Patel, D. et al. 2014. Design and synthesis of non-TZD peroxisome proliferator-activated receptor Î³ (PPARÎ³) modulator. Medicinal Chemistry Research. 23 (4): pp. 2150-2159.

Source Title

Medicinal Chemistry Research

DOI

10.1007/s00044-013-0814-y

ISSN

1054-2523

School

School of Biomedical Sciences

URI

http://hdl.handle.net/20.500.11937/63091

Collection

Curtin Research Publications

Abstract

Thiazolidinediones (TZDs) are an important class of compound used for the treatment of type 2 diabetes, targeting the peroxisome proliferator-activated receptor Î³ (PPARÎ³). Drug-induced hepatotoxicity, edema, and weight gain are the main concerns associated with TZDs. It was unclear whether the side effects observed are target mediated or compound mediated, but most of the TZDs activate PPARÎ³. This obliged developing of a new diverse class of ligands as antihyperglycemic agents including non-TZD PPAR ligands that could be highly effective, safe, and devoid of side effects. Here, we report the design and synthesis of N-(5-chloro-6-((1-phenylpiperidin-4-yl)oxy)pyridin-3-yl) benzenesulfonamide derivatives as non-TZD PPARÎ³ modulators. Â© Springer Science+Business Media 2013.